{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:36:26Z","timestamp":1790476586723,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00277-022-04883-y","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T23:02:38Z","timestamp":1655938958000},"page":"1719-1726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8662-0707","authenticated-orcid":false,"given":"Ofir","family":"Wolach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avraham","family":"Frisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Shargian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Yeshurun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Apel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Vainstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakir","family":"Moshe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shai","family":"Shimony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odelia","family":"Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Bar-On","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishai","family":"Ofran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Raanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boaz","family":"Nachmias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"4883_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM (2021) De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer 127:2049\u20132061","journal-title":"Cancer"},{"key":"4883_CR2","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR et al (2018) CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 36:2684\u20132692","journal-title":"J Clin Oncol"},{"key":"4883_CR3","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","volume":"32","author":"GJ Roboz","year":"2014","unstructured":"Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, O\u2019Connell C, Solomon SR, Pigneux A, Vey N et al (2014) International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia. J Clin Oncol 32:1919\u20131926","journal-title":"J Clin Oncol"},{"key":"4883_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, D\u00f6hner H, Letai A, Fenaux P et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629","journal-title":"N Engl J Med"},{"key":"4883_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S et al (2019) Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol 37:1277\u20131284","journal-title":"J Clin Oncol"},{"issue":"2","key":"4883_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/MOH.0000000000000698","volume":"29","author":"S Shimony","year":"2022","unstructured":"Shimony S, Stone RM, Stahl M (2022) Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Curr Opin Hematol 29(2):63\u201373. https:\/\/doi.org\/10.1097\/MOH.0000000000000698","journal-title":"Current Opinion in Hematology"},{"key":"4883_CR7","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K et al (2021) Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 39:2768\u20132778","journal-title":"J Clin Oncol"},{"key":"4883_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447","journal-title":"Blood"},{"key":"4883_CR9","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA et al (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642\u20134649","journal-title":"J Clin Oncol"},{"key":"4883_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2019","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH et al (2019) Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis 71:1367\u20131376","journal-title":"Clin Infect Dis"},{"key":"4883_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/leu.2017.243","volume":"32","author":"TC Teh","year":"2018","unstructured":"Teh TC, Nguyen NY, Moujalled DM, Segal D, Pomilio G, Rijal S, Jabbour A, Cummins K, Lackovic K, Blombery P et al (2018) Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia 32:303\u2013312","journal-title":"Leukemia"},{"key":"4883_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-140646","volume":"136","author":"RM Stone","year":"2020","unstructured":"Stone RM, DeAngelo DJ, Letai AG, Stewart JM, McGinnis M, Brown F, Fell G, Flammand Y, Konopleva M, Garcia JS et al (2020) Maximal tolerated dose of the BCL-2 inhibitor venetoclax in combination with daunorubicin\/cytarabine induction in previously untreated adults with acute myeloid leukemia (AML). Blood 136:40\u201341","journal-title":"Blood"},{"key":"4883_CR13","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3026(21)00192-7","volume":"8","author":"TM Kadia","year":"2021","unstructured":"Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N et al (2021) Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol 8:e552\u2013e561","journal-title":"Lancet Haematol"},{"key":"4883_CR14","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1200\/JCO.20.00572","volume":"38","author":"CC Chua","year":"2020","unstructured":"Chua CC, Roberts AW, Reynolds J, Fong CY, Ting SB, Salmon JM, MacRaild S, Ivey A, Tiong IS, Fleming S et al (2020) Chemotherapy and venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol 38:3506\u20133517","journal-title":"J Clin Oncol"},{"key":"4883_CR15","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2021-154148","volume":"138","author":"K Kim","year":"2021","unstructured":"Kim K, Kantarjian H, Borthakur G, Takahashi K, Short NJ, DiNardo CD, Jabbour EJ, Chien KS, Daver N, Pemmaraju N et al (2021) A phase II study of CPX-351 plus venetoclax in patients with relapsed\/refractory (R\/R) or newly diagnosed acute myeloid leukemia (AML). Blood 138:1275\u20131275","journal-title":"Blood"},{"key":"4883_CR16","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/bjh.16722","volume":"192","author":"IS Tiong","year":"2021","unstructured":"Tiong IS, Dillon R, Ivey A, Teh TC, Nguyen P, Cummings N, Taussig DC, Latif AL, Potter NE, Runglall M et al (2021) Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br J Haematol 192:1026\u20131030","journal-title":"Br J Haematol"},{"key":"4883_CR17","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","volume":"4","author":"CA Lachowiez","year":"2020","unstructured":"Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N et al (2020) Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4:1311\u20131320","journal-title":"Blood Adv"},{"key":"4883_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791\u2013803","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04883-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04883-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04883-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T13:09:49Z","timestamp":1657717789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04883-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4883"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04883-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]},"assertion":[{"value":"27 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"OW reports receiving speaker Honoraria and past membership on Advisory Board of AbbVie. YM reports receiving speaker Honoraria and past membership on Advisory Board of AbbVie. AF, LS, MY, AA, VV, SS, OA, YBO, YO, PR and BN report no relevant conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}